Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to discover a new approach in which human immunodeficiency virus (HIV) can be eradicated from an infected individual by intensified antiretroviral treatment coupled with immunomodulation. The hypothesis is that eradication is possible only if very potent antiretroviral drugs are delivered in conjunction with an immunomodulatory agent that simultaneously attack the viral reservoirs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

NCT00808002

HIV Infections

COMPLETED PHASE3

Effects of Intensive cART During Acute/Early HIV Infection

NCT01154673

Acute HIV Infection

COMPLETED PHASE2/PHASE3

R5 Integrase Study in HIV-1 Naive Patients

NCT01204905

HIV Infections

COMPLETED NA

Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients

NCT01291459

HIV

UNKNOWN PHASE2

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

NCT01245101

HIV

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to measure the impact of immunomodulation plus treatment intensification on the HIV reservoir in HIV-infected patients who have viral suppression on combination antiretroviral therapy. Treatment regimens first will be intensified by the addition of raltegravir and maraviroc for 8 week followed by immunomodulation with the NIH HIV-rAd5 vaccine plus DNA prime-boost for 24 weeks. The primary endpoint is measurement of change in peripheral cellular HIV DNA. A decrease of 0.5 log is considered significant. A secondary endpoints include change in HIV DNA in the rectal mucosa, immunologic changes in the peripheral blood and safety.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Maraviroc + raltegravir intensification

ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)

Group Type ACTIVE_COMPARATOR

ART intensification (raltegravir)

Intervention Type DRUG

raltegravir 400 mg PO BID for 56 weeks

ART intensification (maraviroc)

Intervention Type DRUG

maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks

Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine

ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)

Group Type EXPERIMENTAL

DNA + HIV-rAd5 vaccine

Intervention Type BIOLOGICAL

4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)

ART intensification (raltegravir)

Intervention Type DRUG

raltegravir 400 mg PO BID for 56 weeks

ART intensification (maraviroc)

Intervention Type DRUG

maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DNA + HIV-rAd5 vaccine

4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)

Intervention Type BIOLOGICAL

ART intensification (raltegravir)

raltegravir 400 mg PO BID for 56 weeks

Intervention Type DRUG

ART intensification (maraviroc)

maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Isentress Selzentry Celsentri

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-1 infection
* At least 3 years of ART without interruption (less than one month cumulative)
* ART regimen unchanged in the 3 months prior to screening
* One HIV plasma viral load (RNA) documented at least 3 years prior to entry, and at least 2 HIV plasma viral load (RNA) documented per year thereafter
* HIV plasma viral load (RNA) ≤ 500 copies/mL at least 3 years prior to entry, and HIV plasma viral load \< 500 copies/mL for \>90% of the measures thereafter
* HIV plasma viral load (RNA) below the limit of detection for all values within the past year (one virologic blip allowed)
* HIV plasma viral load below the limit of detection within 60 days of entry
* CD4+ count ≥ 350 cells/mm3 within 60 days of entry
* Proviral DNA ≥10 and ≤1000 copies/106 PBMCs within 75 days of entry
* Adeno5 neutralizing antibody titers of 250 or less within 75 days of entry
* Hemoglobin ≥ 10 g/dL within 60 days of entry
* Platelets ≥ 100,000 per microliter within 60 days of entry
* Hepatic transaminases (ALT and AST) ≤ 2.5 x ULN within 60 days of entry
* Creatinine clearance \> 50 mL/min by the Cockcroft-Gault equation within 60 days of entry

Exclusion Criteria

* Sexually active men and women who will not practice at least one form of barrier birth control (male partner using condoms, female partner using condoms, other barrier contraception, etc)
* Pregnancy
* Inability or unwillingness to provide informed consent
* HBsAg positive
* HCV antibody positive or HCV RNA detectable
* Previous use of an integrase inhibitor (ie raltegravir) or a CCR5 inhibitor (ie maraviroc, vicriviroc). Use of raltegravir for non-treatment failure indications such as intensification or toxicity switches is allowed.
* Immunologic therapeutic intervention (e.g. IL-2) within the past year
* Participation in another clinical drug or device trial where the last dose of drug was within the past 30 days or an investigational medical device is currently implanted
* Diagnosis of cancer within the last 5 years (except basal cell cutaneous cancers and cutaneous KS not requiring systemic therapy)
* Co-morbid condition with an expected survival of less than 12 months
* History of hypersensitivity to vaccination
* History of autoimmune disease, such as systemic lupus erythematosis (SLE) or Hashimoto's thyroiditis
* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No